Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Grey zones on diabetes in cardiovascular disease. Expert opinion]

Autor: Trevisan R., Grosu A., Avogaro A., Agostoni P., Ceconi C., Genovese S., Bossi A., Piti A., Senni M., Maggioni A. P.

Publikováno v: Giornale italiano di cardiologia (2006). 21(12)

Clinical guidelines, while representing an objective reference to perform correct therapeutic choices, contain grey zones, where recommendations are not supported by solid evidence. In a conference held in Bergamo in October 2018, an attempt was made

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6465264fb3d63f7535870a626224d145
https://pubmed.ncbi.nlm.nih.gov/33231210

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Autor: Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., Huikuri, H. V., Johansson, I., Juni, P., Lettino, M., Marx, N., Mellbin, L. G., Ostgren, C. J., Rocca, Bianca, Roffi, M., Sattar, N., Seferovic, P. M., Sousa-Uva, M., Valensi, P., Wheeler, D. C., Piepoli, M. F., Birkeland, K. I., Adamopoulos, S., Ajjan, R., Avogaro, A., Baigent, C., Brodmann, M., Bueno, H., Ceconi, C., Chioncel, O., Coats, A., Collet, J. -P., Collins, P., Cosyns, B., Di Mario, C., Fisher, M., Fitzsimons, D., Halvorsen, S., Hansen, D., Hoes, A., Holt, R. I. G., Home, P., Katus, H. A., Khunti, K., Komajda, M., Lambrinou, E., Landmesser, U., Lewis, B. S., Linde, C., Lorusso, R., Mach, F., Mueller, C., Neumann, F. -J., Persson, F., Petersen, S. E., Petronio, A. S., Richter, D. J., Rosano, G. M. C., Rossing, P., Ryden, L., Shlyakhto, E., Simpson, I. A., Touyz, R. M., Wijns, W., Wilhelm, M., Williams, B., Windecker, S., Dean, V., Gale, C. P., Hindricks, G., Iung, B., Leclercq, C., Merkely, B., Zelveian, P. H., Scherr, D., Jahangirov, T., Lazareva, I., Shivalkar, B., Naser, N., Gruev, I., Milicic, D., Petrou, P. M., Linhart, A., Hildebrandt, P., Hasan-Ali, H., Marandi, T., Lehto, S., Mansourati, J., Kurashvili, R., Siasos, G., Lengyel, C., Thrainsdottir, I. S., Aronson, D., Di Lenarda, A., Raissova, A., Ibrahimi, P., Abilova, S., Trusinskis, K., Saade, G., Benlamin, H., Petrulioniene, Z., Banu, C., Magri, C. J., David, L., Boskovic, A., Alami, M., Liem, A. H., Bosevski, M., Svingen, G. F. T., Janion, M., Gavina, C., Vinereanu, D., Nedogoda, S., Mancini, T., Ilic, M. D., Fabryova, L., Fras, Z., Jimenez-Navarro, M. F., Norhammar, A., Lehmann, R., Mourali, M. S., Ural, D., Nesukay, E., Chowdhury, T. A.

Publikováno v: European Heart Journal, Vol. 41, No 2 (2020) pp. 255-323
European Heart Journal, 41(2), 255. Oxford University Press
European Heart Journal
European Heart Journal, Oxford University Press (OUP): Policy B, 2020, 41 (2), pp.255-323. ⟨10.1093/eurheartj/ehz486⟩

This is the second iteration of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) joining forces to write guidelines on the management of diabetes mellitus (DM), pre-diabetes, and cardiovascular diseas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a7bfb6acab87ca70ecf4255c5a6b9b7
https://hdl.handle.net/20.500.14017/9c6f1d20-c5aa-4f62-a4da-c8bee50083bb

Specific Properties and Effect of Perindopril in Controlling the Renin–Angiotensin System

Autor: Ferrari, R., Pasanisi, G., Notarstefano, P., Campo, G., Gardini, E., Ceconi, C.

Publikováno v: In American Journal of Hypertension 2005 18(9) Supplement:142-154

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

Autor: Rosano, G.M.C. Tamargo, J. Kjeldsen, K.P. Lainscak, M. Agewall, S. Anker, S.D. Ceconi, C. Coats, A.J.S. Drexel, H. Filippatos, G. Kaski, J.C. Lund, L. Niessner, A. Ponikowski, P. Savarese, G. Schmidt, T.A. Seferovic, P. Wassmann, S. Walther, T. Lewis, B.S.

Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard endpoint

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::c925ba8fb562f935333a5f31c5f8ea6d
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107240